What Is Bimzelx Used For?
Bimzelx (bimekizumab-bkzx) treats moderate to severe plaque psoriasis in adults who need systemic therapy or phototherapy. The FDA approved it in October 2023 for this use.[1] It targets IL-17A and IL-17F proteins, reducing inflammation in psoriatic skin lesions.
How Does Bimzelx Work?
Bimzelx is a monoclonal antibody that blocks both IL-17A and IL-17F cytokines, key drivers of psoriasis inflammation. Dual inhibition sets it apart from drugs like Cosentyx (secukinumab), which targets only IL-17A.[1]
What Other Conditions Does Bimzelx Treat?
- Psoriatic arthritis: Approved in 2024 for active disease in adults.[1]
- Axial spondyloarthritis: Approved June 2024 for non-radiographic and active ankylosing spondylitis in adults.[1]
It's administered as a 320 mg subcutaneous injection every 4 weeks after initial doses.
Who Makes Bimzelx and What's the Pricing?
UCB Pharma manufactures Bimzelx. List price is about $6,000–$7,000 per month before insurance or discounts; patient assistance programs reduce costs for eligible users.[2]
Common Side Effects and Risks
Upper respiratory infections occur in 20–25% of patients. Other risks include fungal infections (e.g., candidiasis), hypersensitivity reactions, and IBD exacerbation. Avoid live vaccines during treatment.[1]
How Does Bimzelx Compare to Other Biologics?
| Drug | Target | Psoriasis Dosing | Key Difference |
|------|--------|------------------|---------------|
| Bimzelx | IL-17A/F | 320 mg Q4W | Dual IL-17 blockade; faster skin clearance in trials |
| Cosentyx | IL-17A | 300 mg Q4W | Single target; established long-term data |
| Tremfya | IL-23 | 100 mg Q8W | Upstream inhibition; also for Crohn's |
| Skyrizi | IL-23 | 150 mg Q12W | Less frequent dosing |
Bimzelx showed superior PASI 90 response (59% at week 16) vs. Cosentyx (50%) in head-to-head trials.[3]
Patent Status and Biosimilars
UCB holds patents on Bimzelx until at least 2036 in the US. No biosimilars are approved; challenges could shorten exclusivity.4 Check DrugPatentWatch.com for expiration details and litigation.
[1]: FDA Prescribing Information for Bimzelx (UCB, 2024). Link
[2]: UCB Pharma pricing data (2024).
[3]: BE VIVID and BE READY trials (Lancet, 2021). Link